2022’s slate of life sciences M&A deals didn’t meet expectations. But the year still featured tens of billions of dollars worth of biopharma acquisitions. Querida Anderson and Eric Sagonowsky discuss the top deals of the year.
Also on the show, Kevin Dunleavy and Fraiser Kansteiner reflect on last year’s largest buyout—Amgen's $28 billion deal for Horizon Therapeutics. They explore what it potentially means for the buyer's market this year. Plus, this week's top headlines and Max Bayer's and Kansteiner's scoop on Johnson & Johnson's R&D overhaul and layoff plans.
To learn more about topics in this episode:
- The top 10 biopharma M&A deals of 2022
- Buyout on Horizon: Amgen floats $28B offer for rare disease drug maker as Sanofi exits bidding war
- J&J's pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries
- Gilead's Trodelvy snags vital breast cancer nod. But AZ, Daiichi's Enhertu casts long shadow
- Vertex pricing under fire—again—as activists press 4 governments for Trikafta generics
- Roche races to regulators after matching AstraZeneca's rare disease blockbuster in phase 3
- Call for nominations: The most influential people in biopharma in 2023
The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.